Can I use Wegovy? Who qualifies and what to expect

Which conditions count towards Wegovy eligibility?

If your BMI sits between 27 and 29.9, you need at least one qualifying weight-related condition to meet the licensed criteria. The conditions that count include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), and obstructive sleep apnoea. Osteoarthritis linked to weight is also relevant. A prescriber considers these alongside your current medicines, medical history, and any contraindications before deciding whether Wegovy is appropriate for you.

BMI thresholds can be 2.5 kg/m² lower for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting differences in cardiovascular and metabolic risk at lower body weights. The NHS BMI calculator is a practical starting point, though it is only one part of the assessment.

A few conditions mean Wegovy is not suitable: a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, previous serious hypersensitivity to semaglutide, and certain gastrointestinal conditions require careful prescriber review. If you have a history of pancreatitis, that conversation needs to happen before any treatment starts. Our full guide to who can use semaglutide goes into these contraindications in more detail.

Does Wegovy work for people close to the lower BMI threshold?

The STEP 1 trial (published in the New England Journal of Medicine) found that adults with obesity or overweight (plus at least one weight-related condition) lost an average of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose, alongside lifestyle changes. That is a meaningful result across a wide range of starting weights, including people who were not far above the eligibility threshold.

If you are trying to understand whether Wegovy could help you reach a specific target, it is worth reading what the evidence actually says about using Wegovy to lose 20 pounds, realistic expectations matter as much as eligibility. NICE notes that if fewer than 5% of body weight is lost after six months on the maintenance dose, continuing treatment should be reviewed. That is not a warning so much as a quality check built into the guidance.

For a more detailed look at how BMI maps onto eligibility in practice, the BMI thresholds for Wegovy page covers the numbers in full. Treatment costs are another practical question at this stage; a factual rundown of what Wegovy costs privately in the UK can help you plan.

What rules out Wegovy, and are there absolute limits?

Wegovy is not licensed for anyone under 18. It is not recommended during pregnancy, while breastfeeding, or for people actively trying to conceive. The MHRA advises using effective contraception while on GLP-1 medicines; there is no equivalent evidence of reduced oral contraceptive absorption with semaglutide that applies to tirzepatide, but your prescriber will review your contraception as part of the consultation.

Some medicines interact with semaglutide in ways that matter clinically. Because Wegovy slows gastric emptying, the absorption of other oral medicines can shift slightly, particularly those with a narrow therapeutic window. Insulin and sulfonylureas used alongside it carry a hypoglycaemia risk. None of this is unusual territory for a prescriber, it just means the assessment needs to be thorough.

If you are currently on Wegovy through another service and considering transferring, a prescriber will want to see evidence of your current dose before approving continuation or a dose increase. That is true of any responsible clinic, not just ours. You can read more about the full Wegovy treatment overview or check how much excess weight Wegovy is typically used to treat if you are still mapping your own situation.

How does the NHS eligibility for Wegovy compare to a private assessment?

NICE recommends semaglutide (Wegovy) under technology appraisal TA875 for use within specialist weight management services, for a maximum of two years, in adults with a BMI of 35 or above and at least one weight-related comorbidity. The ethnic-background thresholds apply here too, and NHS England quotes 32.5 (rather than 35) for Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. NHS waiting lists for specialist services can be long, and not every area has straightforward access.

Private assessment through a regulated online pharmacy works from the licensed SmPC thresholds (BMI ≥30, or ≥27 with a qualifying condition) rather than the narrower NICE criteria. That means more people are clinically eligible through a private route than the NHS currently commissions. The trade-off is cost; treatment is not free. At nume, a GPhC-registered prescriber reads your consultation answers the same day. If approved, your pen is dispatched by 12pm and arrives via DPD the next working day, in plain, unbranded packaging, with tracking on your phone. The practical steps to starting Wegovy page explains what the process looks like from your side.